PROK ProKidney Corp.

NASDAQ
$1.05

ProKidney Corp. (PROK) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.9% since its last earnings release on November 12, 2026.

ProKidney Missed Consensus Estimates
Thursday, November 12, 2026 · 4:10 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.